Sanofi stock advances on earnings and pipeline momentum

Sanofi (FR0000127771) is anchored by €7.3 billion in first-half 2026 revenue and 32.4% growth in business operating income, while the board approved a 10.3% higher dividend for 2025. Those numbers set the tone for Sanofi stock after the latest reporting cycle.

Revenue and margins

Sanofi reported first-half 2026 net sales of €19.0 billion, up 9.3% at constant exchange rates, and business operating income of €6.2 billion, up 7.8% on a reported basis. The group also said diluted earnings per share reached €4.35 in the period, compared with €3.82 a year earlier, a year-over-year increase of 13.9%.

That mix matters because the revenue base is growing while profitability is expanding faster than sales. For investors, the margin profile is now as important as the top line, especially after the company kept its 2026 guidance framework in view of first-half execution.

€19.0 billion first half

The comparison is clear: €19.0 billion in first-half 2026 sales versus a lower prior-year base, €6.2 billion in business operating income, and €4.35 in diluted EPS all point in the same direction. Sanofi also highlighted that 2026 first-half results were supported by specialty care momentum and recurring contributions from key medicines.

One dated market anchor remains useful for context: Sanofi shares on Euronext Paris should be read against the companys continuing scale in European large-cap healthcare, where earnings quality and dividend capacity tend to matter more than short-term volatility. The dividend decision adds another quantified marker to the reporting picture.

Dividend up 10.3%

Sanofi said the board approved a 2025 dividend of €3.92 per share, up 10.3% from €3.55 previously. That is a concrete sign of capital allocation discipline, and it gives the stock a second valuation anchor beyond earnings alone.

The company also reported that first-half 2026 free cash flow reached €3.2 billion, a useful contrast with the earnings line because cash conversion remains central for healthcare investors. A 2026 performance mix with higher sales, higher operating income and stronger cash flow is easier to defend than a sales story alone.

Specialty care mix

Sanofi said specialty care remained the main growth engine in the first half of 2026, led by Dupixent and other core medicines. Dupixent alone generated €6.0 billion in sales in the period, underlining how concentrated product strength can carry group results.

That product concentration is not just a product story. It is also the reason the market keeps checking whether pipeline expansion can broaden growth beyond the current blockbuster base.

Paris listing context

Sanofi stock trades on Euronext Paris as one of Europe`s largest healthcare names, and the reported first-half 2026 figures keep the valuation debate tied to execution rather than narrative. With €19.0 billion in revenue, €6.2 billion in business operating income and a €3.92 dividend, the numbers now define the case more than the slogan.